Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

Cancer

Volumn 104, Issue 3, 2005, Pages 561-569

  Kim, Edward S ^a   Kies, Merrill S ^a   Fossella, Frank V ^a   Glisson, Bonnie S ^a   Zaknoen, Sara ^b   Statkevich, Paul ^b   Munden, Reginald F ^a   Summey, Carmen ^a   Pisters, Katherine M W ^c   Papadimitrakopoulou, Vali ^a   Tighiouart, Mourad ^c   Rogatko, Andre ^c   Khuri, Fadlo R ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Farnesyltransferase inhibitor; Lonafarnib; Paclitaxel; Taxane refractory resistant nonsmall cell lung carcinoma

Indexed keywords

DOCETAXEL; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TAXANE DERIVATIVE;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURVIVAL TIME; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PIPERIDINES; PYRIDINES; REMISSION INDUCTION; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 22544467757     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21188     Document Type: Article

References (26)

1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer Statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol. 1988;6:633-641.
3. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta. 1997;1333:F51-F71.
4. Gibbs JB. Lipid modifications of proteins in the ras superfamily. In: Birnbaumer L, Dickey B, editors. GTPases in biology. New York: Springer-Verlag, 1993:335-344.
5. Rowinsky EK, Windle JJ, von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
6. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
7. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561-565.
8. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras in surgically resected non-small cell lung cancer patients. Oncogene. 1993;8:2407-2412.
9. Kato K, Cox AD, Hisaka MM, et al. Isoprenoid addition of Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 1992;89:6403-6407.
10. Liu M, Bryant MS, Chen J, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgeneic mice. Cancer Res. 1998;58:4947-4956.
11. Nielsen LL, Shi B, Hajian G, et al. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res. 1999;59:5896-5901.
12. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275:30451-30457.
13. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res. 2001;7:1438-1445.
14. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA. 1998;95:1369-1367.
15. Shi B, Yaremko B, Hajian G, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. 2000;46:387-393.
16. Eskens F, Awada A, Cutler D, et al. Phase 1 and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 2001;19:1167-1175.
17. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871-1877.
18. Khuri FR, Glisson BS, Kim ES, et al. Phase I study of the farnesyltransferase inhibitor (FTI) lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004;10:2968-2976.
19. Ashar HR, James L, Gray K, et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) → M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res. 2001;262:17-27.
20. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA. 2000;97:2904-2909.
21. Crespo NC, Ohkanda J, Yen TJ, et al. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem. 2001;276:16161-16167.
22. Hassan KA, Lee H-Y, Chun K-H, et al. Dephosphorlyation and down-regulation of AKT is associated with farnesyltransferase inhibitor (SCH66336) treatment in head and neck squamous cell carcinoma cell lines [abstract]. Proc Am Assoc Cancer Res. 2002;943:4666.
23. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:1760-1766.
24. Khuri FR, Cohen V. Farnesyl transferase inhibitors: a promising future in cancer treatment [commentary]. Clin Lung Cancer. 2002;4:63-64.
25. Massarelli E, Onn A, Zinner R, Khuri FR, Herbst RS. Novel therapeutics for advanced non-small cell lung cancer. In: Giaccone G, Schilsky R, Sondel P, editors. Cancer chemotherapy and biological response modifiers, annual 20. New York: Elsevier Science, 2002:717-7612002.
26. Shin DM, Donato NJ, Cooper M, et al. Epidermal growth factor receptor-targeted therapy with humanized chimeric monoclonal antibody, C225 in combination with cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001;7:1204-1213.